Home News About us Comitato scientifico Iscriviti Utenti Etica Contenuti Guida Faq Stage Contatti ☰
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Nirmatrelvir

Paxlovid

Bibliografia - Quali fonti bibliografiche per Nirmatrelvir?

  1. Aarnoutse R.E. et al., Clin. Pharmacol. Ther., 2005, 78 (6), 664.

  2. Abbas R. et al., Br. J. Clin. Pharmacol., 2011, 71 (4), 522.

  3. Agenzia Italiana del Farmaco – AIFA, Norvir – Riassunto Caratteristiche di Prodotto, 2021, 4 aprile, https://www.fda.gov/media/155050/download (Accesso: febbraio 2022).

  4. Agenzia Italiana del Farmaco – AIFA, Paxlovid – Riassunto caratteristiche di Prodotto, 2022 https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/ (accesso: febbraio 2022).

  5. Aggarwal N.R. et al., Lancet Infect Dis., 2023, Feb 10.

  6. Ahmad B. et al., Int. J. Mol. Sci., 2021, 22 (17), 9124.

  7. Al-Maqbali A. et al., Sultan Qaboos Univ. Med., 2017, 17 (3), 339.

  8. 1989. Antiretroviral Pregnancy Registry Steering Committee, Antiretroviral Pregnancy Registry Interim Report for 1 January. 31 January 2021, Registry Coordinating Center. Available from URL: www.APRegistry.com, Wilmington, NC., 2021.

  9. Badowski M.E. et al., Drugs Context, 2019, 8, 212550.

  10. Barcellos T. et al., Contraception, 2019, 100 (4), 283.

  11. Becker C. et al., Pulm. Circ., 2016, 6 (Suppl. 1), S49.

  12. Berger J.L. et al., Antivir. Ther., 2017, 22 (3), 271.

  13. Brill M.J. et al., Int. J. Antimicrob. Agents, 2017, 49 (2), 212.

  14. Brust J.C.M. et al., Clin. Infect. Dis., 2021, 73 (11), 2083.

  15. Burger D.M. et al., Antivir. Ther., 1997, 2, 149.

  16. Busti A.J. et al., J. Cardiovasc. Pharmacol., 2008, 51 (6), 605.

  17. Castro-Moraga M.E. et al., Andes. Pediatr., 2021, 92 (3), 446.

  18. Catlin N.R. et al., Reprod. Toxicol., 2022, 108, 56.

  19. Cato 3rd A. et al., Clin. Pharmacol. Ther., 1998, 63 (4), 414.

  20. Cato 3rd A. et al., Antimicrob. Agents Chemother., 1998a, 42 (7), 1788.

  21. Chauvin B. et al., Clin. Pharmacokinet., 2013, 52 (10), 815.

  22. Clay P.G., Adams M.M., Ann. Pharmacother., 2003, 37 (2), 202.

  23. Cordova E. et al., Int. J. STD AIDS, 2017, 28 (12), 1259.

  24. Courlet P. et al., Eur. J. Clin. Pharmacol., 2021, 77 (7), 979.

  25. Crommentuyn K.M. et al., 2004, 38 (8), e73.

  26. DeJesus E. et al., Pulm. Circ., 2019, 9 (2), 2045894019848644.

  27. Dekkers B.G.J. et al., AIDS, 2019, 33 (6), 1100.

  28. Deo R. et al., Ann. Intern. Med., 2023, Feb 21. Doi: 10.7326/M22-2381.

  29. Ding R. et al., Clin. Pharmacol. Ther., 2004, 76 (1), 73.

  30. Dingemanse J. et al., Antivir. Ther., 2010, 15 (2), 157.

  31. Dresser G. K. et al., Clin. Pharmacokinet., 2000, 38 (1), 41.

  32. Eeftinck Schattenkerk J.K., Lager P.S., Ned. Tijdschr. Geneeskd., 2013, 157 (14), A5509.

  33. Eng H. et al., Drug Metab. Dispos., 2022, Feb 13, DMD-AR-2021-000801.

  34. Ezzat H.M. et al., Leuk. Lymphoma, 2012, 53 (12), 2390.

  35. European Medicines Agency – EMA, Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023, 2023, 27 Genuary, https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-january-2023 (accesso: febbraio 2023).

  36. Figueiredo J. et al., BMJ Case Rep., 2020, 13 (5), e233712.

  37. Foisy M.M. et al., HIV Med., 2008, 9 (6), 389.

  38. Food and Drug Administration – FDA, Fact Sheet for Healthcare Providers: Emergency Use Authorization foe Paxlovid, 2021, Dicember, https://www.fda.gov/media/155050/download (Accesso: febbraio 2022).

  39. Garaffo R. et al., J. Clin. Pharmacol., 2011, 51 (7), 1071.

  40. Gidal B.E. et al., Epilepsy Res., 2017, 134, 41.

  41. Glesby M.J. et al., Clin. Pharmacol. Ther., 2005, 78 (2), 142.

  42. Granfors M.T. et al., Basic Clin. Pharmacol. Toxicol., 2006, 98 (1), 79.

  43. Greenblatt D.J. et al., Clin. Pharmacol. Ther., 2000, 67 (4), 335.

  44. Greenblatt D.J. et al., J. Acquir. Immune Defic. Syndr., 2000a, 24 (2), 129.

  45. Greenblatt D.J. et al., Br. J. Clin. Pharmacol., 2009, 68 (6), 920.

  46. Greenblatt D.J. et al., J. Clin. Psychopharmacol., 2018, 38 (4), 289.

  47. Hafner V. et al., Clin. Pharmacol. Ther., 2010, 87 (2), 191.

  48. Halford B., Chem. Eng. News. 2021

  49. Hammond J. et al., NEJM, 2022, 386 (15), 1397.

  50. Hesse L.M. et al., J. Clin. Pharmacol., 2006, 46 (5), 567.

  51. Hillebrand-Haverkort M.E. et al., AIDS, 1999, 13 (13), 1803.

  52. Hogeland G.W. et al., Clin. Pharmacol. Ther., 2007, 81 (1), 69.

  53. Hsu A. et al., XI international Conference on AIDS, Abstract Mo.B.1200, 1996, July 7-12, Vancouver.

  54. Hughes C.A. et al., CMAJ, 2007, 177 (4), 357.

  55. Iardino A. et al., BMJ Case Rep., 2018, 2018: bcr2018225130.

  56. Iwamoto M. et al., Antimicrob. Agents Chemother., 2008, 52 (12), 4338.

  57. Jacobs T.G. et al., J. Antimicrob. Chemother., 2022, 77 (3), 568.

  58. James J. et al., J. Laryngol. Otol., 2021, Sep 28, 1.

  59. Jover F. et al., Clin. Neuropharmacol., 2002, 25 (5), 251.

  60. Kakuda T.N. et al., Antimicrob. Agents Chemother., 2011, 55 (5), 2290.

  61. Kaeser B. et al., Antimicrob. Agents Chemother., 2009, 53 (2), 609.

  62. Katezmaier S. et al., Clin. Pharmacol. Ther., 2011, 90 (5), 666.

  63. Kelly D.V. et al., Ann. Pharmacother., 2002, 36 (5), 827.

  64. Khaliq Y. Et al., Br. J. Clin. Pharmacol., 2000, 50 (1), 82.

  65. kharasch E.D. et al., Antimicrob. Agents Chemother., 2008, 52 (5), 1663

  66. Kharasch E.D. et al., Clin. Pharmacol. Ther., 2008, 84 (4), 497.

  67. Kharasch E.D. et al., Clin. Pharmacol. Ther., 2008a, 84 (4), 506.

  68. Kharasch E.D., Stubbert K., Drug Metab. Dispos., 2013, 41 (12), 2166.

  69. Kiser J.J. et al., J. Acquir. Immune Defic. Syndr., 2008, 47 (5), 570.

  70. Kosloski M.P. et al., J. Infect. Dis., 2020, 221 (2), 223.

  71. Kosoglou T. et al. J. Clin. Pharmacol., 2013, 53 (5), 540.

  72. Kouanda S. et al.,BMC Infect. Dis., 2020, 20 (1), 449.

  73. Kwo P.Y. et al., NEJM, 2014, 371 (25), 2375.

  74. Lactmed, 2022, 18 gennaio https://www.ncbi.nlm.nih.gov/books/NBK576869/#nirmatrelvir.Drug_Levels_and_Effects (accesso: febbraio 2022).

  75. Lakatos B. et al., Swiss Med. Wkly, 2014, 144, w13906

  76. Lange N.W. et al., Am. J. Transplant., 2022, Jan 11. Doi:10.1111/ajt.16955.

  77. Lee S.I. et al., Psychosomatic., 2000, 41 (5), 453.

  78. Leveque D. et al., Pharm. World Sci., 2009, 31 (6), 619.

  79. Li P. et al., Cell Res., 2022, Jan 20, 1.

  80. Lohman J.J.H.M. et al., Ann. Pharmacother., 1999, 33, 645.

  81. Loulergue P. et al., Scand. J. Infect. Dis., 2011, 43 (3), 239.

  82. Macchiagodena M. et al., J. Mol.Graph. Model., 2022, 110, 108042.

  83. MacKenzie-Wood A.R. et al., Med. J. Aust., 1999, 170 (1), 46.

  84. Mallikaarjun S. et al., Antimicrob. Agents Chemother., 2016, 60 (10), 5976.

  85. Manchee G.R. et al., Drug Metab. Dispos., 1996, 24 (5), 555.

  86. Mas Serrano M. et al., J, Neurol. Sci., 2020, 15, 415.

  87. McCance-Katz E.F. et al., Clin. Infect. Dis., 2006, 43 Suppl. 4, S235.

  88. Menon R.M. et al. J. Hepatol., 2015, 63 (1), 20.

  89. Mohamedi N. et al., J. Med. Vasc., 2021, 46 (1), 13.

  90. Morcos P.N. et al., Int. J. Clin. Pharmacol. Ther., 2014, 52 (2), 103,

  91. Mueck W. et al., Br. J. Clin. Pharmacol., 2013, 76 (3), 455.

  92. Mukherjee D. et al., J. Pharmacokinet. Pharmacodyn., 2018, 45 (3), 443.

  93. Muirhead G.J. et al., Br. J. Clin. Pharmacol., 2000, 50 (2), 99.

  94. Niu W. et al., Br. J. Clin. Pharmacol., 2021, 87 (7), 2790.

  95. Noyman I. et al., Epilepsia, 2022, 63 (5), 1276.

  96. Olkkola K.T. et al., Anesthesiology, 1999, 91 (3), 681.

  97. Park J. et al., J. Clin. Pharmacol., 2010, 50 (10), 1180.

  98. Patel G. et al., J. Clin. Pharmacol., 2016, 56 (1), 47.

  99. Penzak S.R. et al., J. Acquir. Immune Defic. Syndr., 2005, 40 (5), 573.

  100. Piscitelli S.C. et al., Pharmacotherapy, 2000, 20 (5), 549.

  101. Pollack T.M. et al., Pharmacotherapy, 2009, 29 (11), 1386.

  102. Quellet D. et al., Br. J. Clin. Pharmacol., 1998, 46 (2), 111.

  103. Quellet D. et al., Clin. Pharmacol. Ther., 1998a, 64 (4), 355.

  104. Ramanathan S. et al., J. Acquir. Immune Defic. Syndr., 2007, 46 (2), 160.

  105. Ramanathan S. et al., J. Acquir. Immune Defic. Syndr., 2010, 53 (2), 209.

  106. Sahjpal R. et al., Am. J. Health Syst. Pharm., 2017, 74 (8), 587.

  107. Salerno D.M. et al., Am. J. Transplant., 2022, Mar. 12, doi: 10.1111/ajt.17027.

  108. Sampson M.R. et al., J. Clin. Pharmacol., 2019, 59 (4), 500.

  109. Schmitt C. et al., Pharmacotherapy, 2009, 29 (10), 1175.

  110. Sekar V.J. et al., Br. J. Clin. Pharmacol., 2008, 66 (2), 215.

  111. Sekar V.J. et al., J. Clin. Pharmacol., 2008a, 48 (1), 60.

  112. Sekar V.J. et al., Antivir. Ther., 2008b, 13 (4), 563.

  113. Sekar V. et al., Clin Drug Investig., 2008, 28 (8), 479.

  114. Seymour N. et al., J. Laryngol. Otol., 135 (9), 755.

  115. Sheehan N. L. et al., Ann. Pharmacother., 2006, 40 (1), 147.

  116. Stader F. et al., J. Antimicob. Chemother., 2020, 75 (10), 3084.

  117. Suzuki A. et al., Ther. Drug Monit., 2003, 25 (2), 192.

  118. Szymanski S. et al., J. Clin. Psychiatry, 1991, 52 (1), 21.

  119. Taylor D. et al., Int. Clin. Psychopharmacol., 1999, 14 (3), 185.

  120. Terkeltaub R.A. et al., Arthritis. Rheum., 2011, 63 (8), 2226.

  121. Torti C. et al., The Lancet Regional Health - Europe, 2023, 14 July, DOI:https://doi.org/10.1016/j.lanepe.2023.10068.

  122. Ullrich S. et al., Bioorg. Med. Chem. Lett., 2022, Feb 16, 128629.2022.

  123. van der Lee M.J. et al., Clin. Pharmacol. Ther., 2006, 80 (2), 159.

  124. Van der Lee M. et al., Antivir. Ther., 2007, 12 (7), 1127.

  125. van Heeswijk R.P. et al., J. Antimicrob. Agents, 2014, 69 (9), 2310.

  126. Varis T. et al., Clin. Pharmacol. Ther., 2000, 68 (5), 487.

  127. Vogler M.A. et al., J. Acquir. Immune Defic. Syndr., 2010, 55 (4), 473.

  128. Williams D. et al., HIV Med., 2019, 20 (5), e10.

  129. Wind S. et al., Clin. Drug Investig., 2014, 34 (3), 173.

  130. Wong C.K.H. et al., Lancet Infect Dis., 2023, S1473-3099(22),00873-8.

  131. Wood B. et al., J. int. Assoc. Provid. AIDS care, 2015, 14 (4), 300.

  132. Yakiwchuk E.M. et al., Ann. Pharmacother., 2008, 42 (5), 698.

  133. Yoganathan K. et al., et al., Int. J. STD AIDS, 2017, 28 (3), 297.

  134. Zhang J. et al., J. Antimicrob. Chemother., 2011, 66 (9), 2075.

  135. Zhang J. et al., Antivir. Ther., 2011a, 16 (2), 157.

  136. Zhu L. et al., J. Clin. Pharmacol., 2017, 57 (2), 235.